William R. Foster

William R. Foster

Auto-generated profile, based on publicly available information

William R. Foster

Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Brighton, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
HBHenry J. Bailey
Henry J. Bailey
GBGustavo A. Bezerra
Gustavo A. Bezerra
JMJason R. Marcero
Jason R. Marcero
SPSiladitya Padhi
Siladitya Padhi
WFWilliam R. Foster
William R. Foster
WYWyatt W. Yue
Wyatt W. Yue
5′-aminolevulinate synthase (ALAS) catalyzes the first step in heme biosynthesis, generating 5′-aminolevulinate from glycine and succinyl-CoA. Inherited frameshift indel mutations of human erythroid-specific isozyme ALAS2, within a C-terminal (Ct) extension of its catalytic core that is only present in higher eukaryotes, lead to gain-of-function X-linked protoporphyria (XLP). Here, we report the human ALAS2 crystal structure, revealing that its Ct-extension folds onto the catalytic core, sits atop the active site, and precludes binding of substrate succinyl-CoA. The Ct-extension is therefore an autoinhibitory element that must re-orient during catalysis, as supported by molecular dynamics simulations. Our data explain how Ct deletions in XLP alleviate autoinhibition and increase enzyme activity. Crystallography-based fragment screening reveals a binding hotspot around the Ct-extension, where fragments interfere with the Ct conformational dynamics and inhibit ALAS2 activity. These fragments represent a starting point to develop ALAS2 inhibitors as substrate reduction therapy for porphyria disorders that accumulate toxic heme intermediates.

10 June 2020 in IUCrJ
Verified
Journal Article
Open access
PDF file
GBGustavo A. Bezerra
Gustavo A. Bezerra
WFWilliam R. Foster
William R. Foster
HBHenry J. Bailey
Henry J. Bailey
KHKevin G. Hicks
Kevin G. Hicks
SSSven W. Sauer
Sven W. Sauer
SKS. Koelker
S. Koelker
DHTKD1 is a lesser-studied E1 enzyme among the family of 2-oxoacid dehydrogenases. In complex with E2 (dihydrolipoamide succinyltransferase, DLST) and E3 (dihydrolipoamide dehydrogenase, DLD) components, DHTKD1 is involved in lysine and tryptophan catabolism by catalysing the oxidative decarboxylation of 2-oxoadipate (2OA) in mitochondria. Here, the 1.9 Å resolution crystal structure of human DHTKD1 is solved in complex with the thiamine diphosphate co-factor. The structure reveals how the DHTKD1 active site is modelled upon the well characterized homologue 2-oxoglutarate (2OG) dehydrogenase but engineered specifically to accommodate its preference for the longer substrate of 2OA over 2OG. A 4.7 Å resolution reconstruction of the human DLST catalytic core is also generated by single-particle electron microscopy, revealing a 24-mer cubic scaffold for assembling DHTKD1 and DLD protomers into a megacomplex. It is further demonstrated that missense DHTKD1 variants causing the inborn error of 2-aminoadipic and 2-oxoadipic aciduria impact on the complex formation, either directly by disrupting the interaction with DLST, or indirectly through destabilizing the DHTKD1 protein. This study provides the starting framework for developing DHTKD1 modulators to probe the intricate mitochondrial energy metabolism.

30 September 2026 in EMBO Reports
Verified
Journal Article
Open access
PDF file
SGSandra Maria Martin Guerrero
Sandra Maria Martin Guerrero
TSTommy Shields
Tommy Shields
PCPedro Casado
Pedro Casado
RZRóbert Zach
Róbert Zach
VRVinothini Rajeeve
Vinothini Rajeeve
PCPedro Rodriguez Cutillas
Pedro Rodriguez Cutillas
Greatwall kinase regulates mitotic progression by phosphorylating ENSA and ARPP19, thereby inhibiting PP2A-B55. Moreover, Greatwall has been implicated in oncogenesis, particularly in solid tumours, but the mechanisms by which Greatwall regulates the cell cycle in other malignancies remain unclear. Here, we show that Greatwall regulates cytokinesis and cell cycle progression in acute myeloid leukaemia (AML) cells through a pathway distinct from ENSA-PP2A-B55. AML cells require Greatwall expression and activity to proliferate, as revealed by pharmacological and systematic genetic perturbation experiments. Mechanistically, Greatwall inactivation or genetic depletion does not measurably affect the ENSA–PP2A-B55 pathway. Instead, loss of Greatwall function alters cytokinesis, and the phosphorylation of proteins involved in cytoskeletal organisation and cytokinesis, including MARK3, which we identify as a direct Greatwall substrate in AML cells. Together, these findings reveal that the Greatwall kinase signalling network is wired differently in leukemic cells, thus uncovering a novel mechanism of cell cycle regulation.

8 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RZRóbert Zach
Róbert Zach
AHAlex D. Herbert
Alex D. Herbert
CDCalin-Mihai Dragoi
Calin-Mihai Dragoi
MMMegan Meredith
Megan Meredith
LGLisandra Gadelkarim
Lisandra Gadelkarim
HHHelfrid Hochegger
Helfrid Hochegger
The switch-like G2/M transition and mitotic exit depend on a feedback loop comprising CDK1, Greatwall kinase, and the PP2A-B55α phosphatase. Monogenic disruptions of these regulators impair cellular functions, drive genomic instability, and promote cancer-associated characteristics. Yet how perturbations of this feedback loop interact, and whether their effects depend on cellular context, remain unclear. Here, we assess how combinatorial perturbations of CDK1, Greatwall, and PP2A-B55α affect cell-cycle control in non-transformed RPE-1 and tumour-derived HeLa cells. We identify PP2A-B55α as a context-dependent G2/M repressor with a critical role in cancer cells, where it cooperates with PKMYT1 and, to a lesser extent, WEE1 to prevent premature mitosis. In cancer cells, but not in non-transformed cells, reduced PP2A-B55α activity and Greatwall overexpression produce marked sensitisation to the PKMYT1-selective RP-6306 and modest sensitisation to the WEE1-selective adavosertib. This asymmetric sensitisation reflects a functional separation between WEE1 and PKMYT1 in S- and G2-phase control. Our work outlines fundamental and cell-type-specific contributions of CDK1, Greatwall and PP2A-B55α to cell-cycle regulation and proposes G2/M plasticity as a vulnerability with utility in PKMYT1-targeted therapy.